Oncotarget | MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway
“In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator ...
